- Home
- RIGL vs AUDC Comparison
RIGL vs AUDC Comparison
Compare RIGL & AUDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- AUDC
- Stock Information
- Founded
- RIGL 1996
- AUDC 1992
- Country
- RIGL United States
- AUDC Israel
- Employees
- RIGL N/A
- AUDC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- AUDC Telecommunications Equipment
- Sector
- RIGL Health Care
- AUDC Utilities
- Exchange
- RIGL Nasdaq
- AUDC Nasdaq
- Market Cap
- RIGL 247.1M
- AUDC 266.8M
- IPO Year
- RIGL 2000
- AUDC 1999
- Fundamental
- Price
- RIGL $25.04
- AUDC $8.72
- Analyst Decision
- RIGL Buy
- AUDC Buy
- Analyst Count
- RIGL 5
- AUDC 2
- Target Price
- RIGL $31.30
- AUDC $10.00
- AVG Volume (30 Days)
- RIGL 288.9K
- AUDC 107.3K
- Earning Date
- RIGL 11-07-2024
- AUDC 11-06-2024
- Dividend Yield
- RIGL N/A
- AUDC 4.14%
- EPS Growth
- RIGL N/A
- AUDC 0.25
- EPS
- RIGL 0.22
- AUDC 0.40
- Revenue
- RIGL $157,374,000.00
- AUDC $244,181,000.00
- Revenue This Year
- RIGL $38.26
- AUDC N/A
- Revenue Next Year
- RIGL $24.21
- AUDC $21.93
- P/E Ratio
- RIGL $109.79
- AUDC $21.59
- Revenue Growth
- RIGL 21.65
- AUDC N/A
- 52 Week Low
- RIGL $7.48
- AUDC $7.70
- 52 Week High
- RIGL $29.82
- AUDC $14.45
- Technical
- Relative Strength Index (RSI)
- RIGL 68.80
- AUDC 47.92
- Support Level
- RIGL $22.33
- AUDC $8.13
- Resistance Level
- RIGL $29.16
- AUDC $8.76
- Average True Range (ATR)
- RIGL 2.30
- AUDC 0.31
- MACD
- RIGL 0.41
- AUDC 0.05
- Stochastic Oscillator
- RIGL 69.96
- AUDC 64.65
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.